| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Americas | 241.0 | 239.9 | 233.6 | 244.0 | 224.8 | | | |
| Sports Medicine - Americas | 158.1 | 155.2 | 149.0 | | | | | |
| Sports Medicine Americas | | | | 160.9 | 147.2 | | | |
| Ear, Nose and Throat Americas | | | | 79.0 | 72.4 | | | |
| Total revenues | 378.0 | 368.5 | 354.9 | 355.4 | 324.1 | 307.3 | 279.7 | 243.7 |
| Revenue growth [+] | 2.6% | 3.8% | -0.1% | 9.6% | 5.5% | 9.9% | 14.8% | 13.7% |
| Americas | 0.5% | 2.7% | -4.3% | 8.6% | | | | |
| Sports Medicine - Americas | 1.9% | 4.1% | | | | | | |
| Sports Medicine Americas | | | | 9.3% | | | | |
| Ear, Nose and Throat Americas | | | | 9.2% | | | | |
| Ear Nose and Throat ("ENT") - Americas | -1.7% | 1.3% | | | | | | |
| Cost of goods sold | 116.3 | 108.0 | 103.3 | 110.8 | 90.9 | 92.6 | 86.4 | 70.7 |
| Gross profit | 261.7 | 260.5 | 251.6 | 244.6 | 233.2 | 214.6 | 193.3 | 173.0 |
| Gross margin | 69.2% | 70.7% | 70.9% | 68.8% | 71.9% | 69.9% | 69.1% | 71.0% |
| Selling, general and administrative [+] | 156.1 | 149.3 | 143.7 | 143.4 | 157.7 | 175.9 | 128.7 | 107.2 |
| Sales and marketing | 122.6 | 116.1 | 108.6 | 107.9 | 114.5 | 125.5 | 104.6 | 85.2 |
| General and administrative | 33.5 | 33.2 | 35.1 | 35.5 | 43.2 | 50.4 | 24.1 | 21.9 |
| Research and development | 34.0 | 32.1 | 28.9 | 35.8 | 35.2 | 31.9 | 28.1 | 23.3 |
| Other operating expenses | 39.0 | 15.7 | 82.3 | 11.1 | 40.2 | 24.5 | 41.2 | 8.8 |
| EBITDA [+] | 47.2 | 83.8 | 21.2 | 78.4 | 24.0 | 5.4 | 16.6 | 53.2 |
| EBITDA growth | -43.7% | 294.6% | -72.9% | 227.3% | 345.7% | -67.7% | -68.7% | 1.9% |
| EBITDA margin | 12.5% | 22.7% | 6.0% | 22.1% | 7.4% | 1.7% | 5.9% | 21.8% |
| Depreciation and amortization | 12.5 | 15.6 | 19.3 | 18.9 | 18.6 | 17.5 | 14.2 | 12.3 |
| EBITA | 34.7 | 68.2 | 1.9 | 59.5 | 5.4 | -12.1 | 2.4 | 40.9 |
| EBITA margin | 9.2% | 18.5% | 0.5% | 16.7% | 1.7% | -4.0% | 0.9% | 16.8% |
| Amortization of intangibles | 2.0 | 4.9 | 5.3 | 5.2 | 5.3 | 5.5 | 7.1 | 7.2 |
| EBIT [+] | 32.7 | 63.4 | -3.4 | 54.3 | 0.1 | -17.6 | -4.7 | 33.7 |
| EBIT growth | -48.5% | -1981.7% | -106.2% | 102296.2% | -100.3% | 275.9% | -113.9% | -5.0% |
| EBIT margin | 8.6% | 17.2% | -0.9% | 15.3% | 0.0% | -5.7% | -1.7% | 13.8% |
| Non-recurring items [+] | 0.7 | -0.8 | 12.1 | | | 6.3 | | |
| Asset impairment | | | | | | 6.3 | | |
| Business exit costs | 0.7 | -0.8 | 8.3 | | | | | |
| Interest income | | | | | | | 2.1 | 1.4 |
| Interest income | | | | | | | 2.1 | 1.4 |
| Other income (expense), net [+] | -0.9 | -0.4 | -1.3 | -3.9 | -2.2 | -8.9 | 0.1 | -0.1 |
| Gain (loss) on foreign currency transactions | -1.5 | -0.3 | -0.7 | -3.3 | 1.2 | | | |
| Other | 2.6 | 0.7 | 0.0 | 0.2 | 0.3 | | | |
| Pre-tax income | 31.1 | 63.7 | -16.8 | 50.4 | -2.2 | -32.8 | -2.5 | 35.0 |
| Income taxes | 5.1 | 17.3 | -14.0 | 12.9 | 3.1 | -8.2 | -3.0 | 7.3 |
| Tax rate | 16.3% | 27.2% | 83.3% | 25.6% | | 25.0% | 119.8% | 20.9% |
| Earnings from continuing ops | 22.3 | 42.8 | -6.2 | 34.3 | -33.3 | 10.4 | 0.0 | 27.7 |
| Earnings from discontinued ops | | | 1.9 | -0.4 | -0.5 | -10.4 | | |
| Net income | 22.3 | 42.8 | -4.3 | 33.8 | -33.8 | 0.0 | 0.0 | 27.7 |
| Net margin | 5.9% | 11.6% | -1.2% | 9.5% | -10.4% | 0.0% | 0.0% | 11.4% |
| |
| Basic EPS [+] | $0.79 | $1.54 | ($0.23) | $1.27 | ($1.24) | $391.13 | $0.02 | $1.06 |
| Growth | -48.9% | -778.0% | -117.9% | -202.0% | -100.3% | 2186724.2% | -98.3% | 9.4% |
| Diluted EPS [+] | $0.77 | $1.51 | ($0.23) | $1.25 | ($1.24) | $391.13 | $0.02 | $0.99 |
| Growth | -48.9% | -762.4% | -118.2% | -200.7% | -100.3% | 2299681.9% | -98.3% | 2.7% |
| |
| Shares outstanding (basic) [+] | 28.3 | 27.8 | 27.4 | 27.0 | 26.8 | 0.0 | 0.0 | 26.2 |
| Growth | 2.0% | 1.4% | 1.4% | 0.8% | 100625.3% | -3.1% | -99.9% | 7.5% |
| Shares outstanding (diluted) [+] | 29.0 | 28.4 | 27.4 | 27.3 | 26.8 | 0.0 | 0.0 | 27.9 |
| Growth | 2.0% | 3.7% | 0.1% | 2.0% | 100625.3% | -7.8% | -99.9% | 14.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |